BidaskClub upgraded shares of PDL BioPharma (NASDAQ:PDLI) from a strong sell rating to a sell rating in a research report sent to investors on Friday.
A number of other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of PDL BioPharma from a buy rating to a hold rating in a research report on Monday, January 8th. ValuEngine upgraded shares of PDL BioPharma from a hold rating to a buy rating in a research report on Saturday, November 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $3.33.
PDL BioPharma (PDLI) opened at $3.00 on Friday. The company has a market cap of $463.02, a price-to-earnings ratio of 4.23 and a beta of 0.58. PDL BioPharma has a 52-week low of $1.96 and a 52-week high of $3.55. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.16 and a quick ratio of 3.10.
PDL BioPharma Company Profile
PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.
Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.